A US House of Representatives' subcommittee has cleared proposals for the oversight by the Food and Drug Administration of direct-to-consumer advertising by drugmakers. The more rigorous restrictions were removed, amid concerns that any outright ban or delay would be open to a constitutional challenge under the First Amendment (which protects freedom of speech).
Instead, the Democrat-controlled subcommittee voted 23-nine to give the FDA the authority to fine drug firms up to $250,000 for running "false or misleading" advertisement, according to Reuters. The purpose of a ban, Rep Henry Waxman (Democrat, California) explained, would be "dampening consumer interest in a drug whose risks may be serious but are not yet fully known."
The proposals form part of the House's version of the Prescription Drug User Fees Act (Marketletters passim) which, assuming it is carried in a full session of the 435-member assembly sometime in July, must be reconciled with legislation previously approved by the Senate. President George W Bush is then expected to sign the proposals into law.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze